Abstract

To compare midterm results of cutting balloon angioplasty (CBA) to conventional percutaneous transluminal angioplasty (PTA) for the treatment of short femoropopliteal arterial stenosis. Between February 2004 and June 2006, 84 consecutive patients (49 men; mean age 68.5 years, range 53-89) with a total of 142 focal (<3 cm), calcified femoropopliteal occlusive lesions underwent endovascular treatment via an antegrade approach: 40 patients (67 lesions) were treated with PTA and 44 patients (75 lesions) underwent CBA. Follow-up consisted of clinical examination and color duplex ultrasonography at intervals to 2 years. All treatments were technically successfully, without any major complication. In 4 (6%) of 67 lesions treated with PTA, a self-expanding stent was implanted due to a flow-limiting dissection; no patient treated with CBA had recoil, dissection, or arterial tears requiring stent placement. In the PTA group, primary and secondary patency rates, respectively, were 91.0% and 95.5% at 6 months, 83.1% and 92.4% at 12 months, and 66.6% and 76.5% at 2 years. In the CBA patients, the primary and secondary patency rates, respectively, were 93.2% and 95.9% at 6 months, 90.4% (p<0.001 versus PTA at same interval) and 94.5% at 12 months, and 79.7% (p<0.001) and 85.6% (p<0.001) at 2 years. CBA seems to be a valuable tool in the endovascular treatment of short femoropopliteal stenotic lesions, achieving better patency at midterm compared to conventional PTA.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.